9 September 2014
Hoping to encourage sufficient investments by pharmaceutical companies in expensive gene therapies, which often consist of a single treatment, experts outline an alternative payment model.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/bzZk07rX0jk/140909192126.htm
